MarketCapExport financials
Cardiff Oncology (CRDF)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cardiff Oncology Income Statement 2025-2000 | CRDF
Brief overview of financial results at Cardiff Oncology
The figures are compared over a five-year interval. The revenue attributed to Cardiff Oncology moved from 366 thousand dollars to 593 thousand dollars between the two endpoints. Overall revenue changed by +62%, equal to an annualized rate of about 10.1%. The pace indicates confident and sustained business growth.
EBITDA changed from −18.6 million dollars to −48.6 million dollars (−161%). EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from −5087.5% to −8194.9%. A lower EBITDA share weakens the quality of the result.
The net financial result changed from −$19.3 million to −$45.9 thousand. Losses became smaller, but the business remains unprofitable.
Conclusion
The figures do not all move in the same direction. The financial profile benefits from a larger revenue base and a stronger final result. The weaker side of the profile includes pressure on operating profitability and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Cardiff Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
116 M | 194 M | 78.6 M | 75 M | 235 M | 70.5 M | 9.62 M | 9.78 M | 10.1 M | 58.8 M | 95.4 M | 123 M | 99.3 M | 89.8 M | 35 M | - | - | - | - | - | - | - | - | - | - | - |
Shares |
66.8 M | 47.6 M | 44.7 M | 43.6 M | 39 M | 5.97 M | 5.97 M | 2.33 M | 482 K | 419 K | 364 K | 263 K | 236 K | 181 K | 135 K | - | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
1.74 | 4.08 | 1.76 | 1.72 | 6.01 | 18 | 1.24 | 3.18 | 22.3 | 151 | 389 | 310 | 413 | 499 | 238 | 220 | 168 | 207 | 341 | 475 | 1.47 K | - | - | - | - | - |
Net Income |
-45.9 K | -45.4 K | -41.4 K | -38.7 M | -28.3 M | -19.3 M | -16.4 M | -16.5 M | -24.9 M | -39.2 M | -27.5 M | -14.3 M | -11.8 M | -11.6 M | -2.24 M | -5.45 M | -2.48 M | -5.17 M | -4.68 M | -7.84 M | -5.37 M | -383 K | -482 K | -524 K | -268 K | -14.8 K |
Revenue |
593 K | 683 K | 488 K | 386 K | 359 K | 366 K | 245 K | 378 K | 505 K | 381 K | 313 K | 280 K | 259 K | 450 K | 258 K | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 597 K | 1.81 M | 1.73 M | 629 K | 15.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 245 K | -219 K | -1.31 M | -1.35 M | -316 K | 265 K | 259 K | - | 258 K | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-49 M | -48.7 M | -45.4 M | -39.9 M | -28.9 M | -19.1 M | -16.7 M | -17.1 M | -25.6 M | -40.1 M | -25.3 M | -14.9 M | -10.7 M | -4.85 M | -2.98 M | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
5 K | -39 K | -98 K | - | - | 2 K | - | 25.4 K | 1.03 M | 1.67 M | 1.53 M | 843 K | 17 K | - | 56.6 K | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-48.6 M | -48.2 M | -45 M | -39.7 M | -28.4 M | -18.6 M | -16.2 M | -15.5 M | -22.2 M | -38.3 M | -24.9 M | -14.7 M | -10.6 M | -4.81 M | -2.97 M | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
49.6 M | 49.3 M | 45.9 M | 40.3 M | 29.2 M | 19.5 M | 16.9 M | 16.2 M | 22.1 M | 38 M | 25 M | 15.2 M | 10.9 M | 5.3 M | 3.23 M | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
14.2 M | 12.5 M | 13 M | 13.2 M | 11.8 M | 8.22 M | 5.76 M | 8.01 M | 11.5 M | 11.5 M | 7.92 M | 5.81 M | 6.76 M | 3.38 M | 2.32 M | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Cardiff Oncology
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
66.5 M | 68.4 M | - | 66.9 M | 66.5 M | 66.5 M | 66.5 M | 46.9 M | 44.8 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 43.3 M | 43.3 M | 43.2 M | 42 M | 39.6 M | 38.8 M | 37.2 M | 36.8 M | 23.3 M | 14.5 M | 9.91 M | 8.59 M | 5.82 M | 5.24 M | 4.09 M | 3.83 M | 3.44 M | 1.24 M | 769 K | 40.2 M | 3.04 M | 2.58 M | 31 M | 30.6 M | 30.3 M | 30 M | 29.8 M | 29.7 M | 28.6 M | 24.6 M | 21.8 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 17.9 M | 15.6 M | 15.5 M | 14.7 M | 14.2 M | 12.1 M | 66 M | 10.7 M | 10 M | 9.15 M | 54.1 M |
Net Income |
-13.9 M | -12.3 M | - | -11.3 M | -13.9 M | -13.4 M | - | -11.9 M | -11.8 M | -10 M | - | -9.73 M | -11.2 M | -11.2 M | - | -8.57 M | -10.4 M | -11 M | - | -6.91 M | -6.76 M | -5.18 M | - | -4.5 M | -4.12 M | -4.09 M | - | -4.14 M | -4.13 M | -3.9 M | - | -3.77 M | -3.75 M | -4.79 M | -2.58 M | -4.29 M | -8.05 M | -10 M | -8.55 M | -10.2 M | -10.2 M | -10.3 M | -7.39 M | -2.74 M | -10.2 M | -7.17 M | -4.69 M | -5.38 M | -1.08 M | -3.19 M | -1.04 M | -4.4 M | -5.27 M | -1.11 M | -6.34 M | -11.6 M | -11.6 M | -11.6 M | - | -2.24 M | -2.24 M | -2.24 M |
Revenue |
121 K | 41 K | - | 120 K | 121 K | 109 K | - | 165 K | 163 K | 205 K | - | 141 K | 108 K | 83 K | - | 93 K | 91 K | 74 K | - | 86 K | 71 K | 57 K | - | 16 K | 16 K | 36 K | - | 53.7 K | 69.8 K | 64.7 K | - | 85.9 K | 36.2 K | 21.8 K | 185 K | 20.6 K | 102 K | 95 K | 68 K | 89.1 K | 103 K | 120 K | 79 K | 57.3 K | 49.3 K | 127 K | 56 K | 57.2 K | 55.6 K | 111 K | 47 K | 43.8 K | 49 K | 119 K | 163 K | 212 K | 41.5 K | 34.2 K | - | 55 K | 79.9 K | 89.1 K |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.7 K | 204 K | 366 K | - | 473 K | 338 K | 616 K | - | 425 K | 409 K | 309 K | - | 174 K | 80 K | 176 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-14.8 M | -12.8 M | - | -12 M | -14.8 M | -14.4 M | - | -12.6 M | -12.5 M | -10.9 M | - | -10.8 M | -12.2 M | -12.1 M | - | -8.99 M | -10.4 M | -11.1 M | - | -7 M | -6.89 M | -5.44 M | - | -4.36 M | -4.1 M | -4.12 M | - | -4.21 M | -4.22 M | -3.96 M | - | -3.86 M | -4.44 M | -4.66 M | - | -5.8 M | -5.89 M | -10.1 M | - | -9.92 M | -9.98 M | -10.5 M | - | -6.41 M | -6.63 M | -4.85 M | - | -3.94 M | -3.24 M | -3.26 M | - | -3.08 M | -2.37 M | -2.39 M | - | -1.04 M | -1.25 M | -1.13 M | - | -732 K | -647 K | -720 K |
Interest Expense |
-1 K | -1 K | - | - | -1 K | 7 K | - | 5 K | -38 K | -4 K | - | 21 K | 5 K | -111 K | - | -36 K | -253 K | -49 K | - | 3 K | - | -1 K | - | -6 K | 6 K | -3 K | - | - | - | - | - | 16 | 925 | 24.2 K | - | 37.1 K | 1.57 K | - | - | - | - | - | - | 353 K | 391 K | 390 K | - | 390 K | 54.7 K | 9.5 K | - | 6.26 K | 668 | - | - | - | - | - | - | 56.6 K | 28.1 K | 28.5 K |
EBITDA |
-14.7 M | -12.8 M | - | -11.9 M | -14.7 M | -14.3 M | - | -12.5 M | -12.4 M | -10.8 M | - | - | - | -12 M | - | -8.84 M | -10.4 M | -11 M | - | -6.66 M | -6.89 M | -5.32 M | - | -4.01 M | -3.87 M | -4 M | - | -3.83 M | -3.97 M | -3.83 M | - | -3.15 M | -3.96 M | -4.4 M | - | -4.84 M | -5.24 M | -9.79 M | - | -9.23 M | -9.49 M | -10.3 M | - | -6.16 M | -6.48 M | -4.78 M | - | -3.77 M | -3.13 M | -3.21 M | - | -2.99 M | -2.33 M | -2.37 M | - | -1.01 M | -1.23 M | -1.12 M | - | -724 K | -642 K | -717 K |
Operating Expenses |
14.9 M | 12.9 M | - | 12.1 M | 14.9 M | 14.5 M | - | 12.8 M | 12.7 M | 11.1 M | - | 11 M | 12.3 M | 12.1 M | - | 9.09 M | 10.5 M | 11.1 M | - | 7.08 M | 6.96 M | 5.51 M | - | 4.5 M | 4.14 M | 4.19 M | - | 4.26 M | 4.26 M | 4.02 M | - | 3.94 M | 4.55 M | 4.76 M | 3.97 M | 5.92 M | 5.99 M | 10.2 M | 9.85 M | 10 M | 10.1 M | 10.6 M | 7.46 M | 6.47 M | 6.68 M | 4.98 M | 4.56 M | 4 M | 3.3 M | 3.37 M | 2.9 M | 3.12 M | 2.42 M | 2.51 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.32 M | 6.13 M | - | 3.9 M | 3.32 M | 4.01 M | - | 3.13 M | 3.22 M | 3.13 M | - | 2.94 M | 4.3 M | 3.08 M | - | 3.08 M | 3.09 M | 3.94 M | - | 2.93 M | 2.84 M | 2.24 M | - | 1.64 M | 1.67 M | 1.49 M | - | 1.44 M | 1.43 M | 1.38 M | - | 1.67 M | 2.15 M | 2.5 M | - | 3.66 M | 4.06 M | 2.2 M | - | 2.71 M | 2.47 M | 4 M | - | 1.95 M | 2 M | 1.81 M | - | 1.47 M | 1.31 M | 1.36 M | - | 1.88 M | 1.01 M | 1.35 M | - | 739 K | 810 K | 827 K | - | 586 K | 584 K | 551 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cardiff Oncology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Cayman-islands
Danmark
China
Britain
Australia
Israel
Germany
